CV Sciences, Inc. (CVSI): debt financing — CV Sciences issues $99,614 senior secured convertible note; conversion price cut to $0.03

CV Sciences, Inc.

Issued $99,614.04 senior secured convertible note due July 6, 2027 to an institutional investor.
April 9, 2026 amendment reduced fixed conversion price on prior notes from $0.06 to $0.03 per share.
Third Note conversion price fixed at $0.03 (lesser of $0.03 and prior-day closing price of $0.04).
No interest accrues unless Event of Default; then 18% late fee per annum applies.
Conversion subject to 4.99% beneficial ownership limitation (can be increased to 9.99%).

item 1.01 item 2.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

CV Sciences, Inc. amended senior notes with the Investor maturing July 6, 2027.

Instrument: senior notes
Counterparty: the Investor
Maturity: July 6, 2027
Event: amendment

Exact text from the filing

The April Amendment also extended the maturity date of the Third Note to July 6, 2027.

View on SEC.gov

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

CV Sciences, Inc. incurred senior notes of $99,614.04 with an institutional investor maturing April 6, 2027.

Instrument: senior notes
Principal: $99,614.04
Counterparty: an institutional investor
Maturity: April 6, 2027
Event: incurrence

Exact text from the filing

On April 6, 2026, the Company issued the Investor a Third Note with a principal amount of $99,614.04.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

CV Sciences, Inc. entered into Third Note with the Investor valued at Principal amount $99,614.04, due April 6, 2027 (later extended) (effective 2026-04-06).

Action: entry
Agreement: credit facility
Counterparty: the Investor
Value: Principal amount $99,614.04, due April 6, 2027 (later extended)
Effective: 2026-04-06

Exact text from the filing

disclosed, on February 12, 2025, CV Sciences, Inc., a Delaware corporation (the “Company”) entered into a note purchase agreement (the “Original Purchase Agreement”) with an institutional investor (“Investor”), pursuant to which the Company issued and sold to the Investor a secured promissory note in the original principal amount of $1,600,000 (the “Original Note”).

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

CV Sciences, Inc. amended April Amendment with the Investor valued at Third Note principal amount $99,614.04; conversion price changed to $0.03 per share; maturity date o (effective 2026-04-09).

Action: amendment
Agreement: credit facility
Counterparty: the Investor
Value: Third Note principal amount $99,614.04; conversion price changed to $0.03 per share; maturity date o
Effective: 2026-04-09

Exact text from the filing

On April 9, 2026, the Company and the Investor entered into an agreement (the "April Amendment") to amend the Notes to implement a new fixed conversion price equal to $0.03 per share.

View on SEC.gov

Browse all debt financings →

CV Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-151228

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.